Shandong Sito Bio-technology Co Ltd

Chart & Performance

D1W1MN

P/E

—

P/S

2.15

EPS

—

Div Yield, %

0.17%

Shrs. gr., 5y

1.94%

Rev. gr., 5y

-3.30%

Revenues

1.02b

+4.77%

Net income

-73m

L-17.60%

CFO

159m

-18.48%

Dividend

Sep 24, 20250.01 CNY/sh

Notes

No notes on this company yet

Write a private note on this company, for your eyes only

Add note

Profile

Shandong Sito Bio-technology Co., Ltd. researches, develops, and produces steroid biomedicine intermediates. Its products include 9a-hydroxyandrost, 17a-hydroxyprogesterone, 17a-hydroxy progesterone derivatives, anecort acetate, neomycin sulfate, progesterone intermediate, tylvalosin tartrate, tetraene acetate, androstenedione, bisnoralcohol, norandrostenedione, ethylene deltenone, 16ß and 16a methyl epoxide, and hexahydro-3a-methyl, as well as androsta-1,4-diene-3,17-dione and estra-4,9-diene-3,17-dione. Shandong Sito Bio-technology Co., Ltd. was founded in 2002 and is based in Heze, China.

URL

https://www.sitobiotech.com/

IPO date

Jan 06, 2017

Employees

Domiciled in

Incorporated in

Valuation

Order:

Title CNY in thousands, except ratios and share amounts	FY	FY	FY	FY	FY	FY	FY	FY	FY	FY	FY	FY
Title CNY in thousands, except ratios and share amounts	2025‑12	2024‑12	2023‑12	2023‑00	2022‑12	2022‑00	2021‑12	2020‑12	2019‑12	2018‑12	2017‑12	2016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT